Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Antiviral Res. 2015 Feb 7;116:76–84. doi: 10.1016/j.antiviral.2015.01.011

Figure 3. Effects of per os administered SMDC256160 and/or camostat on survival of BALB/c mice infected with a lethal SARS-CoV.

Figure 3

Ten mice per group were dosed twice a day by oral gavage with SMDC256160 and/or camostat or diluent alone (sterile water) for 9 days beginning 10 hours prior to infection with 10,000 pfu of mouse-adapted SARS-CoV.